Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine for non-alcoholic fatty liver disease
IRCT20230409057859N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of arginine in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Shahid Beheshti University of Medical Sciences. Started May 2023; status: completed.
02
Drugs
arginine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20230409057859N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230409057859N1.